First Trust Advisors LP acquired a new position in shares of Hookipa Pharma Inc (NASDAQ:HOOK) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 13,713 shares of the company’s stock, valued at approximately $103,000. First Trust Advisors LP owned about 0.06% of Hookipa Pharma as of its most recent SEC filing.
Other large investors also recently modified their holdings of the company. Tower Research Capital LLC TRC bought a new position in shares of Hookipa Pharma in the second quarter worth about $40,000. Northern Trust Corp acquired a new position in shares of Hookipa Pharma during the second quarter worth approximately $72,000. Morgan Stanley bought a new stake in shares of Hookipa Pharma during the second quarter valued at approximately $99,000. Vanguard Group Inc. bought a new stake in shares of Hookipa Pharma during the second quarter valued at approximately $538,000. Finally, BlackRock Inc. acquired a new stake in shares of Hookipa Pharma in the second quarter valued at approximately $737,000. 30.71% of the stock is currently owned by hedge funds and other institutional investors.
HOOK has been the subject of several research analyst reports. Zacks Investment Research cut shares of Hookipa Pharma from a “hold” rating to a “sell” rating in a research report on Tuesday, October 15th. Royal Bank of Canada reiterated a “buy” rating and issued a $23.00 price objective on shares of Hookipa Pharma in a research report on Wednesday, August 14th. HC Wainwright reissued a “buy” rating and issued a $15.00 target price on shares of Hookipa Pharma in a research note on Wednesday, November 13th. Finally, ValuEngine upgraded Hookipa Pharma from a “hold” rating to a “buy” rating in a research report on Tuesday, October 1st. One analyst has rated the stock with a sell rating and six have issued a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $17.13.
Hookipa Pharma (NASDAQ:HOOK) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.45) EPS for the quarter, topping the consensus estimate of ($0.66) by $0.21. The business had revenue of $2.04 million for the quarter, compared to analyst estimates of $2.35 million. As a group, equities analysts expect that Hookipa Pharma Inc will post -2.13 earnings per share for the current year.
About Hookipa Pharma
HOOKIPA Pharma Inc, a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.
Receive News & Ratings for Hookipa Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hookipa Pharma and related companies with MarketBeat.com's FREE daily email newsletter.